DSM's XD Tech boosts yields five-10-fold

Dutch life sciences company DSM says that its proprietary XD Technology boosts bioreactor productivity and titers of mammalian cell culture  processes by five to10-fold for the production of proteins and  antibodies.

Recent studies completed at the R&D labs of DSM Biologics in Groningen,  the Netherlands, demonstrated that the yields from CHO-based cell  cultures can be increased five to10-fold over their previous fed-batch  processes using only off the shelf, commercially-available media. The XD  Technology has been tested for antibody and recombinant protein  production across multiple cell lines, and the increase was realized in  all cases.

By dramatically increasing the cell density of a culture, the XD  Technology offers the opportunity to substantially increase titers in a  very short time without changing the cell line or process media. This  can economically save a project already advanced in clinical development  and prevent loss of time.